<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83611">
  <stage>Registered</stage>
  <submitdate>16/02/2009</submitdate>
  <approvaldate>21/04/2009</approvaldate>
  <actrnumber>ACTRN12609000199213</actrnumber>
  <trial_identification>
    <studytitle>Optimising post-operative sedation for Cardiac Intensive Care in patients undergoing elective cardiac surgery involving cardiopulmonary bypass.</studytitle>
    <scientifictitle>The effect of Dexmedetomidine versus Propofol in optimising post-operative sedation in patients undergoing elective cardiac surgery involving cardiopulmonary bypass.</scientifictitle>
    <utrn />
    <trialacronym>OSCI</trialacronym>
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative sedation</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dexmedetomidine - Intravenous dexmedetomidine as a continuous infusion of 0.2-2.5 mcg/kg/h titrated to effect (level of sedation) from end of surgery until weaning for extubation from mechanical ventilation.</interventions>
    <comparator>Propofol (standard treatment) - Intravenous propofol as a continuous infusion of 1-3 mg/kg/h titrated to effect (level of sedation) from the end of surgery until weaning for extubation from mechanical ventilation.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Concentration effect relationship for dexmedetomidine and sedation, blood pressure &amp; heart rate. Concentration of drug will be measured by Liquid Chromatrogrphy-Mass Spectrometry-Mass Spectrometry (LC-MS-MS) assay and concentration-effect relationship for Pharmacodynamic parameters will be modelled using Non Linear Mixed Effects Models.</outcome>
      <timepoint>0, 5, 10, 15, 20, 30, 45, 60 minutes, 2 and 3 hours following termination of drug infusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of dexmedetomidine on sleep-wake cycles and sleep disturbance in the Intensive Care Unit (ICU).  Sleep will be measured using Actigarphy and Processed Electroencephalography (EEG) (Bisprectral Index (BIS)) monitoring.</outcome>
      <timepoint>Sleep will be continuously monitored for up to 2 days post-operation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any patient undergoing elective cardiac surgery involving cardipulmonary bypass 18 years or older who provides written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-allergic to alpha-2 adronoceptor agonists
-alltergic to propofol
-known to be pregnant or breastfeeding
-history of drug abuse
-enrolled in another clinical trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be identified from surgical lists, approched and have the study explained. If they wish to participate written informed consent will be obtained. Patients will then be randomised via sealed envelopes to receive dexmedetomidine or propofol.</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>Private Bag 92019
Auckland Mail Centre
Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Green Lane Research and Educational Fund</fundingname>
      <fundingaddress>P O Box 110042
Auckland 1148</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to investigate the concentration effect relationship for dexmedetomidine and sedation, heart rate and blood pressure in adult patients undergoing elective cardiac surgery involving cardiopulmonary bypass as this is previously unreported.  We also want to examine the effect of dexmedetomidine on postoperative sleep wake cycles compared to propofol.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>Private Bag 92 522
Wellesley Street 1141
Auckland</ethicaddress>
      <ethicapprovaldate>17/11/2008</ethicapprovaldate>
      <hrec>NTX/08/10/094</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Amanda Potts</name>
      <address>Department of Anaesthesiology
University of Auckland
Private Bag 92019
Auckland Mail Centre
Auckland 1142
NZ</address>
      <phone>+64 9 373 7599 ext 89305</phone>
      <fax />
      <email>a.potts@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amanda Potts</name>
      <address>Department of Anaesthesiology
University of Auckland
Private Bag 92019
Auckland Mail Centre
Auckland 1142
NZ</address>
      <phone>+64 9 373 7599 extn 89305</phone>
      <fax />
      <email>a.potts@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amanda Potts</name>
      <address>Department of Anaesthesiology
University of Auckland
Private Bag 92019
Auckland 1142</address>
      <phone>+64 9 373 7599 ext 89305</phone>
      <fax />
      <email>a.potts@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>